{"id":17,"date":"2025-11-19T23:36:58","date_gmt":"2025-11-19T22:36:58","guid":{"rendered":"https:\/\/fhucare.com\/axis-3-new-treatments\/"},"modified":"2026-04-16T12:16:09","modified_gmt":"2026-04-16T10:16:09","slug":"new-treatments","status":"publish","type":"page","link":"https:\/\/fhucare.com\/fr\/research-axes\/new-treatments\/","title":{"rendered":"New Treatments – TREAT\u00a0"},"content":{"rendered":"\n
\n
\n

Leaders<\/strong><\/em><\/h2>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/a>
Xavier Mariette<\/a><\/strong><\/figcaption><\/figure>\n\n\n\n
\"\"<\/a>
Samuel Bitoun<\/a><\/strong><\/figcaption><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\n

Task 1<\/strong><\/em><\/p>\n<\/div>\n\n\n\n

\n

To set-up randomized controlled trials of immunosuppressive biologic drugs in immune related adverse events post immune check-points<\/strong><\/em><\/h3>\n\n\n\n

Samuel Bitoun<\/a><\/strong> is the French PI of a multicentric European<\/strong> prospective trial<\/strong> called CITAR<\/strong>.<\/p>\n\n\n\n

This innovative randomized controlled clinical trial compares for the first time corticosteroids <\/strong>and tocilizumab<\/strong> (anti- IL-6R) in rheumatologic Immune-Related Adverse Events induced by ICI. Arianne Laparra<\/a><\/strong> (Gustave Roussy) participates by referring patients. CITAR is coordinated by Karolinska Institutet<\/strong> and 5 French centers <\/strong>participated in the CITAR clinical trial.<\/p>\n\n\n\n

\n
Read more about CITAR Trial<\/a><\/div>\n<\/div>\n\n\n\n
\"\"<\/a><\/figure>
\n

Watch the presentation of the CITAR Clinical Trial led by Samuel Bitoun<\/a><\/strong><\/strong>, scientific coordinator FHU CARE\u00b2:<\/p>\n\n\n\n

\n